Unusual Presentation of Kawasaki Disease with Multisystem Inflammation and Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: A Case Report

Haena Kim
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Jung Yeon Shim
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Jae-Hoon Ko
Samsung Medical Center

Aram Yang
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Jae Won Shim
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Deok Soo Kim
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Hye Lim Jung
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

Ji Hee Kwak
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

In Suk Sol (✉ issolkk0312@gmail.com)
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine

DOI: https://doi.org/10.21203/rs.3.rs-41276/v1

License: ☇️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Since mid-April 2020, cases of multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease (COVID-19) that mimic Kawasaki disease (KD) have been reported in Europe and North America. However, no cases have been in East Asia, where KD is more prevalent.

**Case presentation:** A previously healthy 11-year-old boy was admitted with a 4-day history of fever and abdominal pain. He had no contact history to any patient with COVID-19. Blood acute inflammatory markers were highly elevated. He was treated with antibiotics for suspected bacterial enteritis, but he suddenly developed hypotension. Inotropics and intravenous immunoglobulin were administered to manage septic shock. On hospitalization day 6, he developed signs and symptoms of KD (conjunctival injection, strawberry tongue, cracked lip, and coronary artery dilatation) in addition to pleural/pericardial effusion and mesenteric lymphadenitis. The results of microbiologic tests, including reverse-transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were negative. Fluorescent immunoassay and enzyme-linked immunosorbent assay revealed abundant IgG antibodies against SARS-CoV-2 in his serum, but no IgM antibodies. He was discharged successfully on day 13.

**Conclusion:** MIS-C may occur in children with a previously asymptomatic COVID-19 infection. A high index of suspicion is required for this novel syndrome in unusual cases of KD or KD shock syndrome with multisystem inflammation, even when there is no clear history of contact or symptoms of COVID-19.

**Background**

Coronavirus disease (COVID-19) has been spreading worldwide since it was first reported in Wuhan, China in December 2019. On March 11, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic (1). Clinical symptoms of COVID-19 in pediatric patients are generally less severe than those in adult patients (2).

However, since mid-April 2020, clusters of children with multisystem inflammatory disease similar to Kawasaki disease shock syndrome (KDSS) have been reported in Europe (3) and North America (4), and some cases appeared to be associated with COVID-19. In these cases, the clinical presentations varied and were consistent with complete or incomplete Kawasaki disease (KD), toxic shock syndrome (TSS), multisystemic hyperinflammation, gastrointestinal symptoms (such as abdominal pain and diarrhea), or pleural/pericardial effusion (5). In some cases, polymerase chain reaction (PCR) and/or antibody tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) yielded positive results. The WHO has provided a preliminary case definition of “multisystem inflammatory syndrome in children and adolescents (MIS-C)” temporally associated with COVID-19 (6).

The prevalence of KD is higher in East Asia than in Europe or North America; however, many MIS-C cases have been reported in Europe and North America, but not in East Asia. Here, we present a case of a South
Korean child who met all criteria of MIS-C (6) (7) with features of incomplete KD or KDSS and was tested positive on the SARS-CoV-2 antibody test.

**Case Presentation**

A previously healthy 11-year-old boy was hospitalised on April 29, 2020 with a 4-day history of fever, nausea, and abdominal pain. He looked acutely ill, but his vital signs were stable. A clear breathing sound was heard, and direct tenderness on the right side of his abdomen was noted. The patient had no medical history other than pneumonia, which he had developed 7 years before. He had not been in contact with any person diagnosed with COVID-19. However, he was in the Philippines from January to the first week of March 2020 and had flown back to Korea. Laboratory findings revealed elevated C-reactive protein (CRP, 121.50 mg/L) and procalcitonin (0.750 mcg/L) levels with a normal whole blood cell count. Abdominal pelvic computed tomography (CT) revealed bowel wall thickening in the terminal ileum and multiple enlarged lymph nodes along the ileocolic artery (Fig. 1A). Even after the administration of intravenous antibiotics, his symptoms persisted, and he developed diarrhea. On hospital day 3, he suddenly developed hypotension (66/36 mmHg), requiring administration of inotropic agents. He was transferred to a pediatric intensive care unit. Laboratory tests showed a white blood cell count of $5.82 \times 10^3/\mu$L (segmented neutrophils, 92.1%) and platelet count of $100 \cdot 10^3/\mu$L. Serum CRP and procalcitonin levels were markedly elevated at 189.50 mg/L and 14.55 mcg/L, respectively. Serum aspartate aminotransferase/alanine aminotransferase level (61/86 U/L), pro-brain natriuretic peptide level (3131 ng/L), prothrombin time (16.1 s; international normalized ratio: 1.52), activated partial thromboplastin time (42.5 s), fibrinogen level (18.61 g/L), and D-dimer level (0.894 µg/mL) were also elevated, but cardiac markers were within the normal range. Cardiomegaly on chest X-ray (CXR) (Fig. 1C) and hypoalbuminemia (22 g/L) were observed on hospital day 4. Based on suspected septic shock, 1 g/kg/day of intravenous immunoglobulin (IVIG, Green Cross corp., Youngin, Korea) was administered for 2 days.

On hospital day 6, the patient’s blood pressure was stable without inotropes, but he developed conjunctival injection, cracked lips (Fig. 2A), and strawberry tongue (Fig. 2B). On echocardiography, the left main coronary artery was dilated and the left anterior descending artery was not tapered (Fig. 3A). Right coronary artery (RCA) dilatation and aneurysmal changes (Fig. 3B) with mild pericardial effusion were identified. On coronary CT, RCA aneurysms or thrombi were not seen, but pleural effusion with lung parenchymal consolidation was newly detected in the absence of respiratory symptoms (Fig. 1D). We diagnosed the patient with KDSS and administered high-dose aspirin (30 mg/kg/day). His fever finally subsided on hospital day 8, but erythematous papular rash and finger desquamation were observed. He was transferred to the general ward and the aspirin dose was reduced to an antithrombotic dose (4 mg/kg/day). Desquamations of the left wrist and perianal area were seen on his last day (day 13) of hospitalisation (Figs. 2C and D). Elevated inflammation markers and coagulopathy had normalized. Cardiomegaly and pleural effusion were not detected on the CXR. Bowel ultrasonography showed that the enlarged lymph nodes were significantly reduced (maximum size from 2.73 to 0.89 cm) (Fig. 1B), and
coronary artery dilatation was markedly reduced on echocardiography after 3 days of IVIG treatment (Figs. 3C and D).

No pathogens were detected in the patient's blood, sputum, stool, or urine. PCR tests for the identification of pathogens in the respiratory tract and stool were negative. PCR tests for SARS-CoV-2 (Seegene, Seoul, South Korea) performed using his nasopharyngeal swab, sputum, serum, urine, and stool showed negative results. However, a serum SARS-CoV-2 specific antibody test using fluorescent immunoassay (Boditech Med Inc., Chuncheon, Korea) yielded positive results for IgG (23.69, cut-off index: >1.1; sensitivity = 95.8%; specificity = 96.7%) and negative results for IgM in his serum (0.08). To minimise the possibility of false-positive and/or non-specific reactions, we repeatedly performed various anti-SARS-CoV-2 antibody test using kits with different target antigens and methodologies. All tests showed positive results. To exclude the potential cross-reactivity of IVIG products (Green Cross Corp., Korea) with SARS-CoV-2 antibody test kits, IVIG products manufactured from the same lots as those administered to the patient were tested. All tests using IVIG products yielded negative results (Table 1). On hospital day 13, the patient was discharged after his symptoms improved.
Table 1
Serologic tests for anti-SARS-CoV-2 antibodies of the patient’s serum and IVIG products administered to the patient

|                                | RDT using gold conjugate | FIA using europium particle | ELISA |
|--------------------------------|--------------------------|-----------------------------|-------|
| **Manufacturer**               | Wells Bio Inc., Seoul, Korea* | SD Biosensor Inc., Suwon, Korea | Boditech Med Inc., Chuncheon, Korea | SD Biosensor Inc., Suwon, Korea | PCL Inc, Seoul, Korea |
| **Target protein**             | RBD†                     | NCP                         | NCP   | NCP   | RBD† & NCP |
| **Cut-off value**              | Visual interpretation    | Visual interpretation       | COI ≥ 1.1 | COI ≥ 1.0 | OD ratio ≥ 1.0 |
| **Patient’s serum**            | IgM: negative            | IgM: negative               | IgM: 0.03 | IgM: 0.89 | Total ab 14.85 |
|                                | IgG: positive            | IgG: positive               | IgG: 20.90 | IgG: 12.7 | |
| **IVIG Lot 381B19006**         |                          |                             |       |       |       |
| concentration                  |                          |                             |       |       |       |
| 10000 mg/dl                    |                          |                             |       |       |       |
| diluted with serum             |                          |                             |       |       |       |
| 1/2: 5000 mg/dL                | 0.06/0.17                |                             | 0.105 | 0.037 |
| 1/4: 2500 mg/dL                | 0.04/0.01                |                             | 0.034 |
| 1/8: 1250 mg/dL                | 0.02/0.00                |                             | 0.034 |
| 1/16: 625 mg/dL                | 0.04/0.00                |                             | 0.026 |
| 1/32: 312.5 mg/dL              | 0.04/0.01                |                             | 0.029 |
| **IVIG Lot 383A19012**         |                          |                             |       |       |       |
| concentration                  |                          |                             |       |       |       |
| 10000 mg/dL                    | 0.06/0.10                |                             | 0.018 |
| diluted with serum             |                          |                             |       |       |       |
| 1/2: 5000 mg/dL                | 0.03/0.00                |                             | 0.021 |
| 1/4: 2500 mg/dL                | 0.03/0.00                |                             | 0.011 |
| 1/8: 1250 mg/dL                | 0.03/0.02                |                             | 0.005 |
| RDT using gold conjugate | FIA using europium particle | ELISA |
|--------------------------|-----------------------------|-------|
| 1/16: 625 mg/dL          | 0.02/0.00                   | 0.018 |
| 1/32: 312.5 mg/dL        | 0.04/0.01                   | 0.021 |

* This kit was assembled in Korea, using the materials manufactured by Jiangsu Medomics Medical Technology (Nanjing, China). †RBD of spike protein

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IVIG, intravenous immunoglobulin; RDT, rapid diagnostic test; FIA, fluorescence immunoassay; ELISA, enzyme-linked immunosorbent assay; RBD, receptor binding domain; NCP, nucleocapsid protein; COI, cut-off index; OD, optical density; ab, antibody; PBS, phosphate-buffered saline

Discussion And Conclusions

There is a growing concern over emerging cases of MIS-C worldwide. MIS-C shows features similar to KD or KDSS in addition to multiple organ inflammation with elevated inflammatory markers in the blood. Although clusters of cases of MIS-C from Europe and North America have been reported during the COVID-19 pandemic, no case has been reported from East Asia. Given the high prevalence of KD or KDSS in East Asia, no report of MIS-C during the pandemic is unusual and merits further investigation. This difference in epidemiology may indicate why MIS-C is different from KD or KDSS, despite having similar features.

The novel multisystem inflammatory syndrome was first suggested by Verdoni L et al. (8) in Italy, and clusters of more cases have since been reported in Europe and the United States. Accordingly, WHO/Centers for Disease Control and Prevention issued a definition of MIS-C and urged awareness and alertness of the disease (6) (9). Our case fulfills all the suggested case definitions.

It was difficult to diagnose our patient’s illness and identify its causes, who was hospitalized for severe enteritis with negative PCR results for SARS-CoV-2. During admission, further symptoms consistent with MIS-C had appeared, and the patient condition improved in response to IVIG. Enteritis symptoms, such as abdominal pain or diarrhea, are rare in KD. However, enteritis symptoms appeared to be common in MIS-C. In a case series from the United Kingdom (UK), diarrhea or abdominal pain were noted on all patients with MIS-C. In another report of MIS-C cases in New York demonstrated that 8 of 17 patients tested positive for SARS-CoV-2 on PCR, while the other 9 patients tested positive on serology (10). Another report of MIS-C cases in New York demonstrated that 8 of 17 patients tested positive for SARS-CoV-2 on PCR, while the other 9 patients tested positive on serology (11). PCR yields negative results after 3–4 weeks of a SARS-CoV-2 infection. Serum IgM disappears within 6–7 weeks of infection, while IgG persists for several months (12). In
previous studies, the interval between the onsets of COVID-19 and MIC-S symptoms were reported as 6 weeks for 24% patients with MIS-C (median: 21 days) (7) (13). Thus, although our patient had no obvious history of exposure to any COVID-19 patient, he may have been exposed to the virus at the airport or somewhere else on his way back to Korea from the Philippines. Although our patient had no respiratory symptoms of COVID-19, IgG antibodies against SARS-CoV-2 were highly positive, and lung parenchymal consolidation was detected on CT. An asymptomatic prior infection could be a cause of MIS-C in our patient.

It is unclear whether MIS-C is caused by a direct SARS-CoV-2 infection or delayed immune response after the infection. It has been suggested that antibody-dependent enhancement of hyperinflammation leads to a more severe outcome in dengue fever (14). Further, in SARS-CoV infection, anti-spike IgG reduced wound healing and provoked lung injury by skewing lung macrophage response and proinflammatory cytokines (15). Likewise, SARS-CoV-2 may induce the hyperinflammatory condition in multiple organs with the antibody-dependent mechanism.

Our patient showed overlapping features of incomplete KD and/or KDSS. However, the features differed from those of KD or KDSS in the following respects: 1) older age; 2) normal cardiac enzyme levels and function and minimal valve regurgitation; 3) coronary dilation in the acute stage and prompt normalization within 3 days after a single IVIG treatment (16) (17). In a recent multicentre study comparing MIS-C with KD, KDSS, and TSS, patients with MIS-C were older and higher levels of inflammatory markers than those with KD, KDSS, or TSS (14).

There is no gold standard serological test for anti-SARS-CoV-2 antibodies. We used various anti-SARS-CoV-2 antibody test kits with different target antigens and methodologies to minimise the possibility of false-positive and/or non-specific reactions; all the tests yielded concordantly positive results. In addition, we evaluated IVIG products administered to the patient at serial dilutions and found that all tests using IVIG showed negative IgG results. For our patient, multiple serological tests suggested a diagnosis of COVID-19.

To our knowledge, no case of MIS-C has been reported in East Asia. Thus far, cases have been concentrated in Europe and North America; however, clinicians from other countries should be aware of this novel syndrome in cases of incomplete KD or KDSS, even when there is no clear history of contact or symptoms of COVID-19, and consider immunomodulatory therapy. Further research and international cooperation are required to investigate the immunopathogenesis of COVID-19 in children.

List Of Abbreviations

MIS-C: Multisystem inflammatory syndrome in children
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
COVID-19: coronavirus disease
WHO: World Health Organization
KDSS: Kawasaki disease shock syndrome
KD: Kawasaki disease
PCR: polymerase chain reaction
MIS-C: multisystem inflammatory syndrome in children and adolescents
CRP: C-reactive protein
CT: computed tomography
CXR: chest X-ray
IVIG: intravenous immunoglobulin
RCA: right coronary artery
TSS: toxic shock syndrome

Declarations

Ethics approval and consent to participate
Not applicable

Consent for publication
Consent has been given by the parents.

Availability of data and materials
Not applicable

Competing interests
The authors declare that they have no competing interests

Funding
Not applicable

Authors' contributions
H Kim gathered the patient data from medical charts and wrote the manuscript. HJ Ko designed the data collection of the patient’s serology and revised the manuscript. A Yang and JW Shim designed the data collection instruments. DS Kim and HL Jung reviewed the manuscript. JY Shim performed the initial analyses and reviewed and revised the manuscript. I Sol and JH Kwak designed the data collection instruments, co-ordinated and supervised data collection, and critically reviewed the manuscript. All authors have read, edited, and approved the final manuscript.

Acknowledgements

We would like to thank the Korean manufacturers for their donations of antibody test kits and Jin Yang Baek for laboratory work.

References

1. Organization WH. Coronavirus disease 2019 2020 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6).
3. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. bmj. 2020;369.
4. DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. The Journal of Pediatrics. 2020.
5. FABRE A, MORAND A. URBINA D. COVID-19 and Kawasaki Like Disease: The Known-Known, the Unknown-Known and the Unknown-Unknown. 2020.
6. Organization WH. Case Report Form for suspected cases of multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19 2020 [Available from: https://www.who.int/publications/i/item/case-report-form-for-suspected-cases-of-multisystem-inflammatory-syndrome-(mis)-in-children-and-adolescents-temporally-related-to-covid-19.
7. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020.
8. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. The Lancet. 2020.
9. Prevention CfDCa. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19) 2020 [cited 2020 1 Jul]. Available from: https://emergency.cdc.gov/han/2020/han00432.asp.
10. Chiotos K, Bassiri H, Behrens EM, Blatz AM, Chang J, Diorio C, et al. Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series. Journal of the Pediatric
11. Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. JAMA. 2020.

12. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020.

13. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020.

14. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. Jama. 2020.

15. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI insight. 2019;4(4).

16. Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. Front Pead. 2018;6:374.

17. Ma L, Zhang Y-Y, Yu H-G. Clinical manifestations of Kawasaki disease shock syndrome. Clin Pediatr. 2018;57(4):428–35.

Figures
Figure 1

Abdomen and chest computed tomography (CT), bowel ultrasonography and simple chest X-ray. A. Abdominal CT finding on the emergency room visit showed enlarged lymph nodes (arrow, maximum length; 2.7 cm) with diffuse bowel wall thickening. B. On hospital day 13 (last day of hospitalization), the enlarged lymph nodes had decreased to 0.89 cm on bowel ultrasonography. C & D. Chest X-ray and CT demonstrated cardiomegaly and pleural effusion with lung parenchymal consolidation on hospital day 4.
Figure 2

Clinical features consistent with Kawasaki disease. A & B. The cracked lip and strawberry tongue newly appeared on hospital day 6. C & D. Desquamation of the perianal area and the wrist were observed on the patient's last day of hospitalization.
Figure 3

Echocardiography findings. A. The left main coronary artery (LMCA, 4.3 mm [Z score 1.64]) and the left anterior descending coronary artery (LAD, 3.8 mm [Z score 2.23]) were not tapered. B. The right coronary artery (RCA, 4.1 mm [Z-score 2.62]) was dilated and aneurysmal change was suspected on hospital day 6. C. On hospital day 13, the size of the LMCA (3.9 mm [Z score 1.04]) and LAD (2.9 mm [Z score 0.38]) had decreased. D. The RCA size had decreased dramatically (3.1 mm [Z-score 0.70]) on the last day of patient’s hospitalization. A The definition of coronary artery length (CAL) has been modified, with CAL defined by a Z score ≥ 2.5, corrected for body surface.